Table 2 Longitudinal data of anti-annexin V serum levels, severity of Raynaud’s phenomenon, HAQ-DI and nailfold capillaroscopy of the 70 SSc patients
From: Anti-annexin V autoantibodies and vascular abnormalities in systemic sclerosis: a longitudinal study
Variable | Moment | p value | |||
|---|---|---|---|---|---|
Baseline | 6 months | 12 months | 24 months | ||
Positive IgG anti-annexin V, n (%) | 11 (15.7) | 12 (17.1) | 9 (12.9) | 9 (12.9) | 0.478 |
Positive IgM anti-annexin V, n (%) | 10 (14.3) | 11 (15.7) | 7 (10.0) | 8 (11.4) | 0.396 |
Patients with active DUs, n (%) | 14 (20.0) | 9 (12.8) | 7 (10.0) | 10 (17.2) | 0.638 |
Gangrene and amputation, n (%) | 4 (5.7) | 3 (4.3) | 2 (2.9) | 5 (7.1) | 0.537 |
Raynaud Condition Score (RCS) | 5.29 ± 2.27 | 4.67 ± 2.10 | 5.24 ± 2. 43 | 5.17 ± 2.41 | 0.015 |
Mean number of DUs | 0.31 ± 0.78 | 0.21 ± 0.59 | 0.16 ± 0.52 | 0.28 ± 0.67 | 0.191 |
HAQ-DI | 0.77 ± 0.05 | 0.71 ± 0.57 | 0.78 ± 0.58 | 0.81 ± 0.60 | 0.051 |
Nailfold videocapillaroscopy | |||||
 Number of capillaries/mm | 7.31 ± 1.00 | 7.08 ± 0.97 | 6.63 ± 1.19 | 6.36 ± 1.21 | < 0.001 |
 Enlarged capillaries | 1.14 ± 0.84 | 1.33 ± 0.87 | 1.60 ± 0.94 | 1.77 ± 0.99 | < 0.001 |
 Giant capillaries | 0.21 ± 0.24 | 0.27 ± 0.30 | 0.43 ± 0.37 | 0.56 ± 0.47 | < 0.001 |
 Microhemorrhages | 0.66 ± 0.62 | 0.59 ± 0.69 | 0.36 ± 0.42 | 0.43 ± 0.43 | < 0.001 |
 Avascular score | 0.9 ± 0.69 | 1.05 ± 0.70 | 1.23 ± 0.74 | 1.34 ± 0.80 | < 0.001 |